|
1
|
Cole JB and Florez JC: Genetics of
diabetes mellitus and diabetes complications. Nat Rev Nephrol.
16:377–390. 2020. View Article : Google Scholar
|
|
2
|
Tervaert TW, Mooyaart AL, Amann K, Cohen
AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Haas M, de Heer
E, et al: Pathologic classification of diabetic nephropathy. J Am
Soc Nephrol. 21:556–563. 2010. View Article : Google Scholar
|
|
3
|
Liang G, Song L, Chen Z, Qian Y, Xie J,
Zhao L, Lin Q, Zhu G, Tan Y, Li X, et al: Fibroblast growth factor
1 ameliorates diabetic nephropathy by an anti-inflammatory
mechanism. Kidney Int. 93:95–109. 2018. View Article : Google Scholar
|
|
4
|
Guilliams M, Thierry GR, Bonnardel J and
Bajenoff M: Establishment and maintenance of the macrophage niche.
Immunity. 52:434–451. 2020. View Article : Google Scholar
|
|
5
|
Klessens CQF, Zandbergen M, Wolterbeek R,
Bruijn JA, Rabelink TJ, Bajema IM and IJpelaar DHT: Macrophages in
diabetic nephropathy in patients with type 2 diabetes. Nephrol Dial
Transplant. 32:1322–1329. 2017.
|
|
6
|
Fu J, Akat KM, Sun Z, Zhang W, Schlondorff
D, Liu Z, Tuschl T, Lee K and He JC: Single-Cell RNA profiling of
glomerular cells shows dynamic changes in experimental diabetic
kidney disease. J Am Soc Nephrol. 30:533–545. 2019. View Article : Google Scholar
|
|
7
|
Smith CI, Islam TC, Mattsson PT, Mohamed
AJ, Nore BF and Vihinen M: The Tec family of cytoplasmic tyrosine
kinases: Mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other
species. BioEssays. 23:436–446. 2001. View Article : Google Scholar
|
|
8
|
Weber ANR, Bittner Z, Liu X, Dang TM,
Radsak MP and Brunner C: Bruton's Tyrosine Kinase: An emerging key
player in innate immunity. Front Immunol. 8:14542017. View Article : Google Scholar
|
|
9
|
Pal Singh S, Dammeijer F and Hendriks RW:
Role of Bruton's tyrosine kinase in B cells and malignancies. Mol
Cancer. 17:572018. View Article : Google Scholar
|
|
10
|
Haselmayer P, Camps M, Liu-Bujalski L,
Nguyen N, Morandi F, Head J, O'Mahony A, Zimmerli SC, Bruns L,
Bender AT, et al: Efficacy and pharmacodynamic modeling of the BTK
inhibitor evobrutinib in autoimmune disease models. J Immunol.
202:2888–2906. 2019. View Article : Google Scholar
|
|
11
|
Rip J, de Bruijn MJW, Appelman MK, Pal
Singh S, Hendriks RW and Corneth OBJ: Toll-Like receptor signaling
drives BTK-mediated autoimmune disease. Front Immunol. 10:952019.
View Article : Google Scholar
|
|
12
|
Wei J, Wang Y, Qi X and Wu Y: Enhanced
Bruton's tyrosine kinase activity in the kidney of patients with
IgA nephropathy. Int Urol Nephrol. 53:1399–1415. 2021. View Article : Google Scholar
|
|
13
|
Kong W, Deng W, Sun Y, Huang S, Zhang Z,
Shi B, Chen W, Tang X, Yao G, Feng X and Sun L: Increased
expression of Bruton's tyrosine kinase in peripheral blood is
associated with lupus nephritis. Clin Rheumatol. 37:43–49. 2018.
View Article : Google Scholar
|
|
14
|
Jain N, Keating M, Thompson P, Ferrajoli
A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T,
et al: Ibrutinib and venetoclax for first-line treatment of CLL. N
Engl J Med. 380:2095–2103. 2019. View Article : Google Scholar
|
|
15
|
Fan Z, Wang Y, Xu X and Wu Y: Inhibitor of
Bruton's tyrosine kinases, PCI-32765, decreases pro-inflammatory
mediators' production in high glucose-induced macrophages. Int
Immunopharmacol. 58:145–153. 2018. View Article : Google Scholar
|
|
16
|
Roschewski M, Lionakis MS, Sharman JP,
Roswarski J, Goy A, Monticelli MA, Roshon M, Wrzesinski SH, Desai
JV, Zarakas MA, et al: Inhibition of Bruton tyrosine kinase in
patients with severe COVID-19. Sci Immunol. 5:eabd01102020.
View Article : Google Scholar
|
|
17
|
Rathinam VA and Fitzgerald KA:
Inflammasome complexes: Emerging mechanisms and effector functions.
Cell. 165:792–800. 2016. View Article : Google Scholar
|
|
18
|
Wang L and Hauenstein AV: The NLRP3
inflammasome: Mechanism of action, role in disease and therapies.
Mol Aspects Med. 76:1008892020. View Article : Google Scholar
|
|
19
|
Hooftman A, Angiari S, Hester S, Corcoran
SE, Runtsch MC, Ling C, Ruzek MC, Slivka PF, McGettrick AF, Banahan
K, et al: The immunomodulatory metabolite itaconate modifies NLRP3
and inhibits inflammasome activation. Cell Metab. 32:468–478.e7.
2020. View Article : Google Scholar
|
|
20
|
Liu D, Yang P, Gao M, Yu T, Shi Y, Zhang
M, Yao M, Liu Y and Zhang X: NLRP3 activation induced by neutrophil
extracellular traps sustains inflammatory response in the diabetic
wound. Clin Sci (Lond). 133:565–582. 2019. View Article : Google Scholar
|
|
21
|
Han Y, Xu X, Tang C, Gao P, Chen X, Xiong
X, Yang M, Yang S, Zhu X, Yuan S, et al: Reactive oxygen species
promote tubular injury in diabetic nephropathy: The role of the
mitochondrial ros-txnip-nlrp3 biological axis. Redox Biol.
16:32–46. 2018. View Article : Google Scholar
|
|
22
|
Mulay SR: Multifactorial functions of the
inflammasome component NLRP3 in pathogenesis of chronic kidney
diseases. Kidney Int. 96:58–66. 2019. View Article : Google Scholar
|
|
23
|
Tang SCW and Yiu WH: Innate immunity in
diabetic kidney disease. Nat Rev Nephrol. 16:206–222. 2020.
View Article : Google Scholar
|
|
24
|
Ram C, Jha AK, Ghosh A, Gairola S, Syed
AM, Murty US, Naidu VGM and Sahu BD: Targeting NLRP3 inflammasome
as a promising approach for treatment of diabetic nephropathy:
Preclinical evidences with therapeutic approaches. Eur J Pharmacol.
885:1735032020. View Article : Google Scholar
|
|
25
|
Weber ANR: Targeting the NLRP3
inflammasome via BTK. Front Cell Dev Biol. 9:6304792021. View Article : Google Scholar
|
|
26
|
Ito M, Shichita T, Okada M, Komine R,
Noguchi Y, Yoshimura A and Morita R: Bruton's tyrosine kinase is
essential for NLRP3 inflammasome activation and contributes to
ischaemic brain injury. Nat Commun. 6:73602015. View Article : Google Scholar
|
|
27
|
Purvis GSD, Collino M, Aranda-Tavio H,
Chiazza F, O'Riordan CE, Zeboudj L, Mohammad S, Collotta D, Verta
R, Guisot NE, et al: Inhibition of Bruton's TK regulates macrophage
NF-κB and NLRP3 inflammasome activation in metabolic inflammation.
Br J Pharmacol. 177:4416–4432. 2020.
|
|
28
|
O'Riordan CE, Purvis GSD, Collotta D,
Krieg N, Wissuwa B, Sheikh MH, Ferreira Alves G, Mohammad S,
Callender LA, Coldewey SM, et al: X-Linked immunodeficient mice
with no functional bruton's tyrosine kinase are protected from
sepsis-induced multiple organ failure. Front Immunol.
11:5817582020. View Article : Google Scholar
|
|
29
|
Li XQ, Chang DY, Chen M and Zhao MH:
Deficiency of C3a receptor attenuates the development of diabetic
nephropathy. BMJ Open Diabetes Res Care. 7:e0008172019. View Article : Google Scholar
|
|
30
|
Liu J, Lee GY, Biggers JD, Toth TL and
Toner M: Low cryoprotectant concentration rapid vitrification of
mouse oocytes and embryos. Cryobiology. 98:233–238. 2021.
View Article : Google Scholar
|
|
31
|
Weinerman R, Ord T, Bartolomei MS,
Coutifaris C and Mainigi M: The superovulated environment,
independent of embryo vitrification, results in low birthweight in
a mouse model. Biol Reprod. 97:133–142. 2017. View Article : Google Scholar
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
33
|
Birnbaum Y, Bajaj M, Yang HC and Ye Y:
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the
Nlrp3/ASC inflammasome and attenuates the development of diabetic
nephropathy in mice with type 2 diabetes. Cardiovasc Drugs Ther.
32:135–145. 2018. View Article : Google Scholar
|
|
34
|
Moreno JA, Gomez-Guerrero C, Mas S, Sanz
AB, Lorenzo O, Ruiz-Ortega M, Opazo L, Mezzano S and Egido J:
Targeting inflammation in diabetic nephropathy: A tale of hope.
Expert Opin Investig Drugs. 27:917–930. 2018. View Article : Google Scholar
|
|
35
|
Wen Y and Crowley SD: The varying roles of
macrophages in kidney injury and repair. Curr Opin Nephrol
Hypertens. 29:286–292. 2020. View Article : Google Scholar
|
|
36
|
Nagata M: Podocyte injury and its
consequences. Kidney Int. 89:1221–1230. 2016. View Article : Google Scholar
|
|
37
|
Agrawal S, He JC and Tharaux PL: Nuclear
receptors in podocyte biology and glomerular disease. Nat Rev
Nephrol. 17:185–204. 2021. View Article : Google Scholar
|
|
38
|
Zhou L, Chen X, Lu M, Wu Q, Yuan Q, Hu C,
Miao J, Zhang Y, Li H, Hou FF, et al: Wnt/β-catenin links oxidative
stress to podocyte injury and proteinuria. Kidney Int. 95:830–845.
2019. View Article : Google Scholar
|
|
39
|
Puelles VG, Bertram JF and Moeller MJ:
Quantifying podocyte depletion: Theoretical and practical
considerations. Cell Tissue Res. 369:229–236. 2017. View Article : Google Scholar
|
